$PainReform (PRFX.US)$ PainReform (Nasdaq: PRFX) provided an...

$PainReform (PRFX.US)$ PainReform (Nasdaq: PRFX) provided an update on its Phase 3 clinical trial of PRF-110 for post-surgical pain management in bunionectomy patients. While the trial showed statistically significant superiority over placebo in pain reduction during the first 48 hours post-surgery, the company revealed that data from the final 24-hour period could not be clarified to meet the study's primary endpoint 72-hour requirement. As a result, the trial did not achieve its primary endpoint.

The company has initiated R&D activities to better understand and refine PRF-110's pharmaco-kinetics and pharmaco-dynamics based on study data. Management plans to use high-level, in-vitro models to address the 72-hour requirement issue before conducting additional clinical work. The company is also reviewing strategic options.